Indication
Please refer to section 4.1 of the Summary of product characteristics in the product information document.
Loading your page…
Loading your page…
Hidradenitis Suppurativa;Arthritis, Psoriatic;Psoriasis;Crohn Disease;Arthritis, Juvenile Rheumatoid;Uveitis;Arthritis, Rheumatoid;Colitis, Ulcerative;Spondylitis, Ankylosing
Marketing Authorisation Holder: Boehringer Ingelheim International GmbH
EMA Authorisation: 10/11/2017
INN: adalimumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Cyltezo: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.